gsk 2189242a
Vaccineexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2008 (NCT00707798)
Timeline
Indications
Studied for
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2189242a
- gsk 2189242a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01545375 | Phase 2 | May 1, 2012 | GlaxoSmithKline |
| NCT01262872 | Phase 2 | Feb 9, 2011 | Department of State for Health and Social Welfare, The Gambia, GlaxoSmithKline, Medical Research Council, The Gambia, PATH, University of London |
| NCT01204658 | Phase 2 | Sep 1, 2010 | GlaxoSmithKline |
| NCT00985751 | Phase 2 | Nov 1, 2009 | GlaxoSmithKline |
| NCT00896064 | Phase 2 | May 1, 2009 | GlaxoSmithKline |
| NCT00707798 | Phase 1 | Jun 30, 2008 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2008 |
| Department of State for Health and Social Welfare, The Gambia | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Medical Research Council, The Gambia | Government | 1 | 0 | 1 | 2011 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1